Skip to main content
Enter your The Contraceptive Pipeline Database username.
Enter the password that accompanies your username.
TDF + LNG Vaginal Ring
Tenofovir Disoproxil Fumarate (TDF) +Levonorgestrel Vaginal Ring
July 12, 2016
Active Pharmaceutical Ingredient (API):
tenofivir disoproxil fumarate (TDF)
Potential Multi-Purpose Technology (MPT):
leave in place for 30 days
Albert Einstein College of Medicine
A clinical trial conducted in 2014 in New York evaluated the ring in 60 women over 14 days. The trial assessed the ring's safety and measured how much of the drug is released and the properties of the ring after use.
Other drugs could potentially be integrated into the ring to prevent other sexually transmitted infections -- a feature that could increase user rates.
The ring has a polymer construction; its elastomer swells in the presence of fluid, delivering up to 1,000 times more of the drug than current intravaginal ring technology.
Download Product Report